Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Paolo Pederzoli

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5105839727, A5108095182. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  2. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  3. The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging. Co-author DOI 10.4103/eus.eus_67_17↗
  4. Variation of tumoral marker after radiofrequency ablation of pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.085↗
  5. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. Last author DOI 10.1111/hpb.12073↗
  6. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1016/j.amjsurg.2011.03.008↗
  7. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile? Co-author DOI 10.1016/j.surg.2012.05.017↗
  8. Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. Co-author DOI 10.1007/s00595-010-4419-5↗
  9. Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Co-author DOI 10.1016/j.dld.2010.09.010↗
  10. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer. Co-author DOI 10.1021/pr100213b↗
  11. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Co-author DOI 10.1245/s10434-011-1769-1↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giovanni Butturini · 6 shared papers, 2011–2026 · strength 0.50
  2. Roberto Girelli · 4 shared papers, 2016–2026 · strength 0.44
  3. Isabella M. Frigerio · 3 shared papers, 2016–2026 · strength 0.38
  4. Filippo Scopelliti · 2 shared papers, 2018–2026 · strength 0.33
  5. Paolo Regi · 2 shared papers, 2018–2026 · strength 0.33
  6. Alessandro Giardino · 2 shared papers, 2018–2026 · strength 0.33
  7. Erica Pizzocaro · 1 shared paper, 2026 · strength 0.25
  8. Roberta Vella · 1 shared paper, 2026 · strength 0.25
  9. Claudio Bassi · 5 shared papers, 2011–2017 · strength 0.21
  10. Roberto Salvia · 4 shared papers, 2011–2017 · strength 0.18
  11. Mirko D’Onofrio · 4 shared papers, 2011–2017 · strength 0.17
  12. Massimo Falconi · 5 shared papers, 2011–2013 · strength 0.15
  13. Stefano Partelli · 4 shared papers, 2011–2013 · strength 0.13
  14. Giuliano Barugola · 4 shared papers, 2011–2013 · strength 0.13
  15. Stefano Crippa · 4 shared papers, 2011–2013 · strength 0.13
  16. Riccardo De Robertis · 2 shared papers, 2016–2017 · strength 0.11
  17. Salvatore Paiella · 2 shared papers, 2016–2017 · strength 0.11
  18. Paola Capelli · 3 shared papers, 2011–2012 · strength 0.09
  19. Antonio Pea · 1 shared paper, 2018 · strength 0.08
  20. Helga Bertani · 1 shared paper, 2018 · strength 0.08
  21. Michèle Milella · 2 shared papers, 2011 · strength 0.04
  22. Giuseppe Malleo · 1 shared paper, 2011 · strength 0.03
  23. Giovanni Marchegiani · 1 shared paper, 2011 · strength 0.03
  24. Domenico Tamburrino · 1 shared paper, 2011 · strength 0.03
  25. Stefano Cereda · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.